BMS_IM101042_Baseline_WB_study. BMS_IM101042_Baseline_WB_study

The goal of this study is to define the molecular signatures of SLE patients at baseline in BMS IM101042 trial. IM101042 (NCT00119678) is a phase IIb, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept vs placebo on a background of oral glucocorticosteroids in the treatment of subjects with systemic lupus erythematosus and the prevention of subsequent lupus flares, sponsored by Bristol-Myers Squibb. Overall design: Total RNA from patients with SLE were collected, and profiled together with samples from normal healthy controls.